JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) and raises the price target from $35 to $37.
November 03, 2023 | 7:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagonist Therapeutics' price target has been raised from $35 to $37 by JMP Securities, maintaining a Market Outperform rating.
The news of JMP Securities raising the price target for Protagonist Therapeutics while maintaining a Market Outperform rating is likely to be seen as a positive signal by the market, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100